Optimizing First-Line Therapy for Advanced-Stage Classic Hodgkin Lymphoma

Presenter: Ranjana H. Advani

Goals of first-line therapy in classic Hodgkin lymphoma (cHL) should focus on balancing risk versus benefit to the individual while increasing efficacy and decreasing toxicity. Overall, the ABVD regimen is well tolerated but slightly less effective, with a better safety profile compared with escalated BEACOPP. BV-AVD is somewhere in between ABVD and escalated BEACOPP on the cure/morbidity scale. Interim PET is predictive, but new prognostic biomarkers are emerging that may better identify patients at high risk for treatment failure. In patients with interim PET-negative cHL, de-escalating therapy does not impact overall survival along 1) with no proven role for radiotherapy. cHL is largely a disease of young people, and the choice of treatment should always take into account the potential for both short- and long-term toxicity with the goal of optimizing survivorship.

Disclosures: Dr. Advani has disclosed receiving consulting fees from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Gilead Sciences, Inc., Incyte Corporation, Roche Laboratories, Inc., and sanofi-aventis U.S.; and receiving grant/research support from Cytier Therapeutics, Forty Seven, Inc., Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Pharmacyclics, Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.

Correspondence: Ranjana H. Advani, MD, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305. Email: radvani@stanford.edu
  • 1.

    SEER Program (www.SEER.cancer.gov) SEER* STAT data base: Incidence-SEER research Data of registries, Nov 2020 Sub 91975-2018), National cancer Institute, DCCPS, Surveillance Research Program, Released April 2021, based on the November 2020 submission.

  • 2.

    Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016;374:24192429.

  • 3.

    Straus DJ, Dlugosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8:e410421.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Press OW, Li H, Schoder H, et al. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:20202007.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Zinzani PL, Broccoli A, Gioia DM, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 2016;34:13761385.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Trotman J, Barrington SF. The role of PET in first-line treatment of Hodgkin lymphoma. Lancet Haematol 2021;8:e6779.

  • 7.

    Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019;134:12381246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018;36:454462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Rigacci L, Puccini B, Broccoli A, et al. Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. Ann Hematol 2020;99:283291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Gallamini A, Rossi A, Patti C, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol 2020;38:39053913.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Anderson RA, Remedios R, Kirkwood AA, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma: a secondary analysis of a randomised phase 3 trial. Lancet Oncol 2018;19:13281337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Demeestere I, Racape J, Dechene J, et al. Gonadal function recovery in patients with advanced Hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011). J Clin Oncol 2021;39:32513260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Huntington SF, von Keudell G, Davidoff AJ, et al. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma [published online October 4, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.00122

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Ramchandren R, Domingo-Domenech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol 2019;37:19972007.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Viviani S, Mazzocchi A, Pavoni C, et al. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. Hematol Oncol 2020;38:501508.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Plattel WJ, Visser L, Diepstra A, et al. Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol 2020;190:4044.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018;36:454462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018;131:24132425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Borchmann S, Cirillo M, Goergen H, et al. Pretreatment vitamin D deficiency is associated with impaired progression-free and overall survival in Hodgkin lymphoma. J Clin Oncol 2019;37:35283537.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 350 350 349
PDF Downloads 216 216 216
EPUB Downloads 0 0 0